El-Hefny A
Pharmatherapeutica. 1983;3(6):388-92.
An open study was carried out in 74 wheezy infants and children, average age 16 months, to assess the efficacy and tolerance of ketotifen given in the form of a syrup at a dosage of 0.02 to 0.03 mg/kg body weight twice daily over a period of 12 weeks. Treatment was assessed as being successful, by both parents and physician, in 62 (84%) of the patients. Wheeze completely disappeared in 42 (57%) patients, cough in 50 (67%) and bronchial hypersecretion in 47 (64%). Patients who developed a superimposed respiratory infection during the treatment period had milder symptoms than usual; these lasted for a shorter time and in most patients it was not necessary to give antibiotics. Forty-one of the 62 patients who had responded successfully to ketotifen suffered a relapse when treatment was withdrawn at the end of the trial period. Ketotifen was well-tolerated by the majority of patients. The side-effect most frequently reported by the parents was dry mouth, which occurred in 21 patients.
对74名喘息婴幼儿及儿童开展了一项开放性研究，这些患儿平均年龄为16个月，旨在评估以糖浆形式给予酮替芬的疗效及耐受性，剂量为0.02至0.03毫克/千克体重，每日两次，为期12周。家长和医生均评估62名（84%）患者治疗成功。42名（57%）患者喘息完全消失，50名（67%）患者咳嗽消失，47名（64%）患者支气管分泌物过多症状消失。在治疗期间出现叠加呼吸道感染的患者症状比平时轻；这些症状持续时间较短，大多数患者无需使用抗生素。在试验期结束停药时，62名对酮替芬治疗成功反应的患者中有41名复发。大多数患者对酮替芬耐受性良好。家长报告最频繁的副作用是口干，21名患者出现此症状。
